Chemistry:Coblopasvir
From HandWiki
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.[2]
In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]
References
- ↑ "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis 27 (1): 45–51. January 2020. doi:10.1111/jvh.13208. PMID 31520460.
- ↑ 2.0 2.1 "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International 40 (11): 2685–2693. November 2020. doi:10.1111/liv.14633. PMID 33047868.
 |  |
